Trial · NCT02155660
Results by group174
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 174
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Benralizumab 10 mg | 0.99 | 95% Confidence Interval 0.87 to 1.13 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | 1.21 | 95% Confidence Interval 1.08 to 1.37 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | 1.09 | 95% Confidence Interval 0.96 to 1.23 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS>=220/uL | Placebo | 1.17 | 95% Confidence Interval 1.04 to 1.32 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Benralizumab 10 mg | 1.23 | 95% Confidence Interval 1.03 to 1.46 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Benralizumab 30 mg | 1.27 | 95% Confidence Interval 1.05 to 1.53 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Benralizumab 100 mg | 1.21 | 95% Confidence Interval 1.00 to 1.45 | Exacerbations per year | |
| Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for Patients With Baseline EOS<220/uL | Placebo | 1.18 | 95% Confidence Interval 0.98 to 1.41 | Exacerbations per year | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Benralizumab 10 mg | 0.021 | Standard Deviation 0.346 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | 0.011 | Standard Deviation 0.289 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | 0.033 | Standard Deviation 0.291 | Liter | |
| Mean Change From Baseline to Week 56 in Pre-bronchodilator FEV1 (L) Value for Patients With Baseline EOS>=220/uL | Placebo | 0.016 | Standard Deviation 0.292 | Liter | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 10 mg | -7.733 | Standard Deviation 14.996 | Percentage | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | -8.674 | Standard Deviation 17.910 | Percentage | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | -7.257 | Standard Deviation 15.989 | Percentage | |
| Mean Change From Baseline in SGRQ Total Score for Patients With Baseline EOS>=220/uL | Placebo | -6.863 | Standard Deviation 16.344 | Percentage | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 10 mg | -2.18 | Standard Deviation 6.78 | Score on a scale | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 30 mg | -2.43 | Standard Deviation 7.18 | Score on a scale | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Benralizumab 100 mg | -2.36 | Standard Deviation 6.67 | Score on a scale | |
| Mean Change From Baseline in CAT Total Score for Patients With Baseline EOS>=220/uL | Placebo | -2.36 | Standard Deviation 6.54 | Score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02155660/results